Technical Analysis for PRTC - PureTech Health plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Up | Up |
Historical PRTC trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
MACD Bullish Centerline Cross | Bullish | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 12.16% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 12.16% | |
Narrow Range Bar | Range Contraction | 12.16% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Gap Down Partially Closed | 34 minutes ago | |
Gapped Down (Full) | 34 minutes ago | |
3x Volume Pace | 34 minutes ago | |
2x Volume Pace | 34 minutes ago | |
1.5x Volume Pace | 34 minutes ago |
Get a Trading Sidekick!
- Earnings date: ???
PureTech Health plc Description
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Pharmaceutical Industry Immunology Health Sciences Medication Monoclonal Antibody Gastrointestinal Dysfunction Urology Schizophrenia Nervous System Disorders Biomarker Milk Central Nervous System Disorders Specialty Drugs Neurology Dementia Psychiatry Hematologic Malignancies Hematopoietic Stem Cell Chronic Disease Alzheimer's Choline Chronic Diseases Boehringer Ingelheim Immune Mediated Diseases Inflammatory Disorders Exosome Galectin Cognitive Dysfunction Psychosis Biomarker Technology Kar Xt Lymphedema Parkinson's Diseases Puretech Health
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 63.95 |
52 Week Low | 33.0 |
Average Volume | 1,783 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 54.38 |
20-Day Moving Average | 54.98 |
10-Day Moving Average | 55.02 |
Average True Range | 3.95 |
ADX | 32.3 |
+DI | 36.93 |
-DI | 19.91 |
Chandelier Exit (Long, 3 ATRs ) | 48.12 |
Chandelier Exit (Short, 3 ATRs ) | 62.35 |
Upper Bollinger Band | 60.57 |
Lower Bollinger Band | 49.40 |
Percent B (%b) | 0.77 |
BandWidth | 20.32 |
MACD Line | 0.18 |
MACD Signal Line | 0.51 |
MACD Histogram | -0.3224 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 65.46 | ||||
Resistance 3 (R3) | 64.63 | 61.31 | 64.21 | ||
Resistance 2 (R2) | 61.31 | 59.41 | 61.73 | 63.80 | |
Resistance 1 (R1) | 59.66 | 58.24 | 60.49 | 60.49 | 63.38 |
Pivot Point | 56.34 | 56.34 | 56.76 | 56.76 | 56.34 |
Support 1 (S1) | 54.69 | 54.44 | 55.52 | 55.52 | 52.62 |
Support 2 (S2) | 51.37 | 53.27 | 51.79 | 52.20 | |
Support 3 (S3) | 49.72 | 51.37 | 51.79 | ||
Support 4 (S4) | 50.55 |